Venous thrombosis and oral contraceptives: Current status

Women's Health

Volumn 2, Issue 5, 2006, Pages 761-772

  Tchaikovski, Svetlana ^a   Tans, Guido ^a   Rosing, Jan ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Blood coagulation; Oral contraceptives; Venous thrombosis

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CYPROTERONE ACETATE; DESOGESTREL; DROSPIRENONE; ETHINYLESTRADIOL; FIBRINOGEN; GESTAGEN; GESTODENE; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROTEIN C; PROTEIN S; PROTHROMBIN; TISSUE FACTOR PATHWAY INHIBITOR;

ACTIVATED PROTEIN C RESISTANCE; BLOOD CLOTTING; CIGARETTE SMOKING; CONTRACEPTION; DATA ANALYSIS; DISEASE ASSOCIATION; DRUG FORMULATION; DRUG USE; DRUG WITHDRAWAL; FEMALE; FIBRINOLYSIS; GENE MUTATION; HEMOSTASIS; HEREDITY; HUMAN; OBESITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; VEIN THROMBOSIS;

EID: 33749514430     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.2.5.761     Document Type: Review

References (88)

1. Makepeace AW, Weinstein GL, Friedman MH: The effect of progestin and progesterone on ovulation in the rabbit. Am. J. Physiol. 119, 512-516 (1937).
2. Connell EB: Contraception in the prepill era. Contraception 59, 7S-10S (1999).
3. Jordan WM: Pulmonary embolism. Lancet 18, 1146-1147 (1961).
4. McWilliam RS, Macdonald AJ, Lindsay I: Thrombophlebitis following the use of norethynodren (Enovid). Can. Med. Assoc. J 88, 1032-1033 (1963).
5. Schatz IJ, Smith RF, Breneman GM, Bower GC: Thromboembolic disease associated with norethynodrel: report of six cases. JAMA 188, 493-495 (1964).
6. Inman WH, Vessey MP, Westerholm B, Engelund A: Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. Br. Med. J. 2, 203-209 (1970).
7. Stadel BV: Oral contraceptives and cardiovascular disease (second of two parts). N. Engl. J. Med. 305, 672-677 (1981).
8. Burkman RT: Current controversies: hormone replacement therapy and breast cancer. Obstet. Gynecol. Surv. 58, 633-635 (2003).
9. Oral contraceptives and thromboembolism. IPPF Med. Bull. 1, 4 (1967).
10. Farley TM, Meirik O, Collins J: Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks. Hum. Reprod. Update 5, 721-735 (1999).
11. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization collaborative study of cardiovascular disease and steroid hormone contraception. Lancet 346, 1582-1588 (1995).
12. Herings RM, Urquhart J. Leufkens HG: Venous thromboembolism among new users of different oral contraceptives. Lancet 354, 127-128 (1999).
13. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP: Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346, 1593-1596 (1995).
14. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C: Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346, 1589-1593 (1995).
15. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD: Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 312, 83-88 (1996).
16. Spitzer WO: The 1995 pill scare revisited: anatomy of a non-epidemic. Hum. Reprod. 12, 2347-2357 (1997).
17. Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR: Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 349, 83-88 (1997).
18. Ory HW: Epidemiology of venous thromboembolic disease and OC use. Dialogues Contracept. 5, 4-7, 10 (1996).
19. Andersen BS, Olsen J, Nielsen GL. et al.: Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism. Thromb. Haemost. 79, 28-31 (1998).
20. Lidegaard O, Edstrom B. Kreiner S: Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 65, 187-196 (2002).
21. Farmer RD, Todd JC, Lewis MA, MacRae KD, Williams TJ: The risks of venous thromboembolic disease among German women using oral contraceptives: a database study. Contraception 57, 67-70 (1998).
22. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM: Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler. Thromb. Vasc. Biol. 19, 700-703 (1999).
23. Lewis MA, MacRae KD, Kuhl-Habichl D, Bruppacher R, Heinemann LA, Spitzer WO: The differential risk of oral contraceptives: the impact of full exposure history. Hum. Reprod. 14, 1493-1499 (1999).
24. Heinemann LA, Garbe E, Farmer R, Lewis MA: Venous thromboembollsm and oral contraceptive use: a methodological study of diagnostic suspicion and referral bias. Eur. J. Contracept. Reprod. Health Care 5, 183-191 (2000).
25. Heinemann LA, Lewis MA, Assmann A, Thiel C: Case-control studies on venous thromboembolism: bias due to design? A methodological study on venous thromboembolism and steroid hormone use. Contraceptton 65, 207-214 (2002).
26. Walker AM: Newer oral contraceptives and the risk of venous thromboembolism. Contraception 57, 169-181 (1998).
27. Bloemenkamp KW, Rosendaal FR, Buller HR, Helmerhorst FM, Colly LP. Vandenbroucke JP: Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch. Intern. Med. 159, 65-70 (1999).
28. Vasilakis-Scaramozza C, Jick H: Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 358, 1427-1429 (2001).
29. Rosendaal FR: Venous thrombosis: a multicausal disease. Lancet 353, 1167-1173 (1999).
30. Pabinger I, Schneider B: Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors. Thromb. Haemost. 71, 548-552 (1994).
31. Legnani C, Palareti G, Guazzaloca G et al.: Venous thromboembolism in young women: role of thrombophilic mutations and oral contraceptive use. Eur. Heart J. 23, 984-990 (2002).
32. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR: Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344, 1453-1457 (1994).
33. Nightingale AL, Lawrenson RA, Simpson EL, Williams TJ, MacRae KD, Farmer RD: The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur. J. Contracept. Reprod. Health Care 5, 265-274 (2000).
34. Abdollahi M, Cushman M, Rosendaal FR: Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb. Haemost. 89, 493-498 (2003).
35. Cushman M, Yanez D, Psaty BM et al.: Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly: the Cardiovascular Health Study. Cardiovascular Health Study Investigators. Am. J. Epidemiol. 143, 665-676 (1996).
36. De Pergola G, De Mitrio V, Giorgino F et al.: Increase in both pro-thrombotic and anti-thrombotic factors in obese premenopausal women: relationship with body fat distribution. Int. J. Obes. Relat. Metab. Disord. 21, 527-535 (1997).
37. Middeldorp S, Meijers JC, van den Ende AE et al.: Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb. Haemost. 84, 4-8 (2000).
38. Tans G, Curvers J, Middeldorp S et al.: A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb. Haemost. 84, 15-21 (2000).
39. Meijers JC, Middeldorp S, Tekelenburg W et al.: Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Thromb. Haemost. 84, 9-14 (2000).
40. Dahlback B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc. Natl Acad. Sci. USA 90, 1004-1008 (1993).
41. Bertina RM, Koeleman BP, Koster T et al.: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369, 64-67 (1994).
42. de Visser MC, van Hylckama Vlieg A, Tans G et al.: Determinants of the APTT-and ETP-based APC sensitivity tests. J. Thromb. Haemost. 3, 1488-1494 (2005).
43. Gennari LC, Blanco AN, Dominguez MP, Grosso SH, Lazzari MA: Endogenous or exogenous coagulation factor level and the response to activated protein C. Thromb. Res. 118, 269-273 (2005).
44. de Visser MC, Rosendaal FR, Bertina RM: A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 93, 1271-1276 (1999).
45. The Oral Contraceptive and Hemostasis Study Group: The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. Contraception 67, 173-185 (2003).
46. The Oral Contraceptive and Hemostasis Study Group: An open label, randomized study to evaluate the effects of seven monophasic oral contraceptive regimens on hemostatic variables: outline of the protocol. Contraception 59, 345-355 (1999).
47. Harris GM, Stendt CL, Vollenhoven BJ, Gan TE, Tipping PG: Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives. Am. J. Hematol. 60, 175-180 (1999).
48. Kemmeren JM, Algra A, Meijers JC et al.: Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. Blood 103, 927-933 (2004).
49. Koenen RR, Christella M, Thomassen LG, Tans G, Rosing J, Hackeng TM: Effect of oral contraceptives on the anticoagulant activity of protein S in plasma. Thromb. Haemost. 93, 853-859 (2005).
50. Olivieri O, Friso S, Manzato F et al.: Resistance to activated protein C in healthy women taking oral contraceptives. Br. J. Haematol. 91, 465-470 (1995).
51. Rosing J, Tans G, Nicolaes GA et al.: Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br. J. Haematol. 97, 233-238 (1997).
52. Rodeghiero F, Tosetto A: Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann. Intern. Med. 130, 643-650 (1999).
53. Tans G, van Hylckama Vlieg A, Thomassen MC et al.: Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br. J. Haematol. 122, 465-470 (2003).
54. Curvers J, Thomassen MC, Nicolaes GA et al.: Acquired APC resistance and oral contraceptives: differences between two functional tests. Br. J. Haematol. 105, 88-94 (1999).
55. Gris JC, Jamin C, Benifla JL, Quere I, Madelenat P, Mares P: APC resistance and third-generation oral contraceptives: acquired resistance to activated protein C, oral contraceptives and the risk of thromboembolic disease. Hum. Reprod. 16, 3-8 (2001).
56. Gris JC, Nouvellon-Cochery E, Mares P: Increased resistance to activated protein C in women taking third-generation oral contraceptives? Blood 104, 1908-1909 (2004).
57. Odlind V, Milsom I, Persson I, Victor A: Can changes in sex hormone binding globulin predict the risk of venous thromboembotism with combined oral contraceptive pills? Acta Obstet. Gynecol. Scand. 81, 482-490 (2002).
58. Mashchak CA, Lobo RA, Dozono-Takano R et al.: Comparison of pharmacodynamic properties of various estrogen formulations. Am. J. Obstet. Gynecol. 144, 511-518 (1982).
59. Mainwaring R, Hales HA, Stevenson K et al.: Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives. Contraception 51, 149-153 (1995).
60. van Rooijen M, Silveira A, Hamsten A, Bremme K: Sex hormone-binding globulin - a surrogate marker for the prothrombotic effects of combined oral contraceptives. Am. J. Obstet. Gynecol. 190, 332-337 (2004).
61. van Vliet HA, Frolich M, Christella M et al.: Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens. Hum. Reprod. 20, 563-568 (2005).
62. Poulter NR, Chang CL, Farley TM, Meirik O: Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications. Lancet 354, 1610 (1999).
63. Gerstman BB, Piper JM, Freiman JP et al.: Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembollsm. Int. J. Epidemiol. 19, 931-936 (1990).
64. Vasilakis C, Jick H, del Mar Melero-Montes M: Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 354, 1610-1611 (1999).
65. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM: A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88, 3698-3703 (1996).
66. Doutremepuich F, Aguejouf O, Belougne-Malfatti E, Doutremepuich C: Fibrinogen as a factor of thrombosis: experimental study. Thromb. Res. 90, 57-64 (1998).
67. van Hylckama Vlieg A, Rosendaal FR: High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J. Thromb. Haemost., 1, 2677-2678 (2003).
68. Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM: Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma levels. Blood 106, 4176-4183 (2005).
69. Koster T, Blann AD, Briet E. Vandenbroucke JP, Rosendaal FR: Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345, 152-155 (1995).
70. Tsai AW, Cushman M, Rosamond WD et al.: Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am. J. Med. 113, 636-642 (2002).
71. van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR: High levels of factor IX increase the risk of venous thrombosis. Blood 95, 3678-3682 (2000).
72. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR: High levels of coagulation factor XI as a risk factor for venous thrombosis. N. Engl. J. Med. 342, 696-701 (2000).
73. Martinelli I, Mannucci PM, De Stefano V et al.: Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 92, 2353-2358 (1998).
74. Dahm A, Van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina RM, Sandset PM: Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 101, 4387-4392 (2003).
75. Amini-Nekoo A, Futers TS, Moia M, Mannucci PM, Grant PJ, Ariens RA: Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. Br. J. Haematol. 113, 537-543 (2001).
76. Brugge JM, Tans G, Rosing J, Castoldi E: Protein S levels modulate the activated protein C resistance phenotype induced by elevated prothrombin levels. Thromb. Haemost. 95, 236-242 (2006).
77. Smirnov MD, Safa O, Esmon NL, Esmon CT: Inhibition of activated protein C anticoagulant activity by prothrombin. Blood 94, 3839-3846 (1999).
78. Tripodi A, Chantarangkul V, Mannucci PM: Hyperprothrombinemia may result in squired activated protein C reistance. Blood 96, 3295-3296 (2000).
79. Winkler UH: Hemostatic effects of third-and second-generation oral contraceptives: absence of a causal mechanism for a difference in risk of venous thromboembolism. Contraception 62, 11S-20S (2000).
80. Kluft C: Renewed interest in haemostasis changes induced by oral contraceptives (OCs). Thromb. Haemost. 84, 1-3 (2000).
81. Svensson PJ, Dahlback B: Resistance to activated protein C as a basis for venous thrombosis. N. Engl. J. Med. 330, 517-522 (1994).
82. Humphries SE, Cook M, Dubowitz M, Stirling Y, Meade TW: Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet 1, 1452-1455 (1987).
83. Haverkate F, Samama M: Familial dysfibrinogenemia and thrombophilla, Report on a study of the SSC Subcommittee on Fibrinogen. Thromb. Haemost. 73, 151-161 (1995).
84. Lane DA, Bayston T, Olds RJ et al.: Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb. Haemost. 77, 197-211 (1997).
85. Reitsma PH: Protein C deficiency: summary of the 1995 database update. Nucleic Acids Res. 24, 157-159 (1996).
86. Gandrille S, Borgel D, Sala N et al.: Protein S deficiency: a database of mutations - summary of the first update. Thromb. Haemost. 84, 918 (2000).
87. Moatti D, Seknadji P, Galand C et al.: Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects: impact of the V264M substitution on plasma levels of TFPI. Arterioscler. Thromb. Vasc. Biol. 19, 862-869 (1999).
88. Castaman G, Tosetto A, Simioni M, Ruggeri M, Madeo D, Rodeghiero, F: Phenotypic APC resistance in carriers of the A20210 prothrombin mutation is associated with an increased risk of venous thrombosis. Thromb. Haemost. 86, 804-808 (2001).